This look back at outcomes for 316 patients receiving upfront immune checkpoint inhibition for advanced cutaneous melanoma reports a longer mean treatment-free survival after combo ipi-nivo (12 months) compared with either single-agent nivo (9 months) or pembro (11 months). | Gupta, JAMA Netw Open 2023
